<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Einstein (Sao Paulo)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Einstein (Sao Paulo)</journal-id>
      <journal-title-group>
        <journal-title>Einstein</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1679-4508</issn>
      <issn pub-type="epub">2317-6385</issn>
      <publisher>
        <publisher-name>Instituto de Ensino e Pesquisa Albert Einstein</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26018146</article-id>
      <article-id pub-id-type="pmc">4943788</article-id>
      <article-id pub-id-type="publisher-id">S1679-45082015RC2829</article-id>
      <article-id pub-id-type="doi">10.1590/S1679-45082015RC2829</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Breast necrosis induced by the use of coumadin: case report and review of literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ejzenberg</surname>
            <given-names>Dani</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Neusquen</surname>
            <given-names>Lucienne Pereira Del Grossi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rolnik</surname>
            <given-names>Daniel Lorber</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lozinsky</surname>
            <given-names>Adriana Chebar</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Piato</surname>
            <given-names>Jos&#xE9; Roberto Morales</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Hospital das Cl&#xED;nicas, Faculdade de Medicina, Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brazil.</aff>
      <aff id="aff2"><label>2</label>Faculdade de Medicina do ABC, Santo Andr&#xE9;, SP, Brazil.</aff>
      <author-notes>
        <corresp>Corresponding author: Dani Ejzenberg &#x2013; Avenida Republica do L&#xED;bano, 1,843 &#x2013; Ibirapuera &#x2013; Zip code: 04501-002 &#x2013; S&#xE3;o Paulo, SP, Brazil &#x2013; Phone: (55 11) 5055-1010 &#x2013; E-mail: <email>daejz@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jul-Sep</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jul-Sep</season>
        <year>2015</year>
      </pub-date>
      <volume>13</volume>
      <issue>3</issue>
      <fpage>417</fpage>
      <lpage>419</lpage>
      <history>
        <date date-type="received">
          <day>12</day>
          <month>4</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>2</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The coumadin-induced skin necrosis is rare and occurs more frequently in the breasts, thighs and buttocks. We describe the first case of coumadin necrosis of the breast in Brazil in a 62-year-old patient.</p>
      </abstract>
      <kwd-group>
        <kwd>Necrosis/chemically induced</kwd>
        <kwd>Warfarin/adverse effects</kwd>
        <kwd>Breast/pathology</kwd>
        <kwd>Case reports</kwd>
      </kwd-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="10"/>
        <page-count count="3"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Anticoagulant therapy is commonly prescribed in the medical practice and one of the most used is sodium warfarin.</p>
      <p>Skin and subcutaneous tissue necrosis is an extremely rare complication, and its incidence ranges from 0.01% to 0.1%. The most common affected sites by this necrosis are breast, buttocks and thighs.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup> The first case of skin necrosis affecting the breast was reported by Flood et al. in 1943.<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup> Since then, almost 200 cases of skin necrosis have been reported so far, but less than 40 cases involved the breast tissue.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup>
</p>
      <p>This event has an irreversible course of action, and early diagnosis and surgical debridement are recommended to prevent significant morbidity and mortality.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 62-year-old patient was admitted to the <italic>Hospital das Cl&#xED;nicas</italic>, in S&#xE3;o Paulo (SP), because of pain in her right breast, swelling and darkening which had commenced 3 days before. The symptoms started on the nipple and spread to the whole right breast. Six days before the onset of the complaints, she started to take sodium warfarin 2.5mg/day, for treatment of deep vein thrombosis on her left leg, however, she did not receive heparin simultaneously. The thrombosis occurred due to complications of a first brachytherapy session to treat an advanced cervical cancer. The patient was also taking angiotensin-converting enzyme inhibitor (captopril 150mg/day) for arterial hypertension and phenobarbital 50mg/day for epilepsy. She denied regular alcohol intake or smoking.</p>
      <p>Upon admission, she was in regular general condition, without fever, and blood pressure of 130x90mmHg. Her body mass index was 32. The abdominal, pulmonary and cardiologic tests were normal. Her left breast was normal while right breast was swollen and had a large ulceration with a necrotic basis involving the nipple and the central area (<xref ref-type="fig" rid="f01">Figure 1</xref>).</p>
      <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Coumadin necrosis of the right breast</title></caption><graphic xlink:href="1679-4508-eins-13-3-0417-gf01"/></fig>
</p>
      <p>Laboratory tests showed hematocrit of 29%, hemoglobin of 9.8mg/dL, white cells count of 6,450 and a platelet count of 142,000/mL. Prothrombin time was 14.7 seconds (normal: 11 seconds) with an international normalized ratio (INR) of 1.3 and normal partial thromboplastin time. Her fibrinogen was normal and fibrin-split products were high (578&#x3BC;g/mL). The diagnostic hypothesis was necrosis due to warfarin use on the right breast. After diagnosis, the patients initiated treatment with high doses of heparin and vitamin K. After four days of treatment no improvements were seen and the patient was submitted to simple mastectomy. No intercurrence was observed and heparin administration was re-initiated 12 hours after the surgery. The patient did well postoperatively and was discharged. An adequate anticoagulant therapy with a warfarin dose of 2.5mg/day was established, without further complications.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Skin necrosis is an unusual complication of anticoagulant therapy, and the breast involvement occurs only 10 to 15% of cases.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup> The majority of necrotic lesions appears in areas of excessive subcutaneous tissue. Such lesions often affect breasts, thighs, arms, buttocks, hands, digits, legs, feet, nose, face, abdomen, back and penis.<sup>(<xref rid="B5" ref-type="bibr">5</xref>)</sup> Women are much more affected than men. Currently, multiple lesions have been reported in 35% of the cases, sometimes symmetrically.<sup>(<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B5" ref-type="bibr">5</xref>)</sup>
</p>
      <p>A literature review of reports in English language including 25 papers described 38 reports of breast necrosis after the use of warfarin. In these reports, patients&#x2019; age ranged 16 to 93 years old.<sup>(<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B5" ref-type="bibr">5</xref>)</sup> No significant difference between the involvement of right and left breasts was reported, being bilateral necrosis also observed.<sup>(<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>)</sup> Typically, this condition is seen in middle-aged obese women who are receiving warfarin therapy for deep venous thrombosis or other thromboembolic diseases, such as the case we report here.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>)</sup>
</p>
      <p>The initial lesion is a well-defined erythematous and painful area, which appears in 3 to 6 days after the beginning of anticoagulation.<sup>(<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>)</sup> This area may develop a <italic>peau d&#x2019;orange</italic> aspect.<sup>(<xref rid="B5" ref-type="bibr">5</xref>)</sup> The area evolves into a black ecchymosed area, which progresses to dry gangrene.<sup>(<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>)</sup> Histology shows cutaneous infarcts, haemorrhages, breakdown of precapillary arterioles, fibrin deposits and no evidence of vascular or perivascular inflammation.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>)</sup> Some advanced cases can mimic inflammatory carcinoma, and that is why early biopsy helps in the differential diagnosis.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
</p>
      <p>The exact etiology and the reason for its predilection for fat tissue remain unclear, but many authors believe that it is a multifactorial condition, which can include trauma, inadequate blood perfusion and variation of temperature.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B7" ref-type="bibr">7</xref>)</sup> The probable mechanism unleashing this complication is a small cutaneous vessels thrombosis due to the inhibition of proteins C and S, and vitamin K-dependent endogenous anticoagulants. Such situation occurs before the inhibition of other factors and leads to thrombotic tendency among people who have homozigotic, heterozigotic or acquired protein C or S deficiencies.<sup>(<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>)</sup> For this reason, many authors recommend the concomitant administration of heparin in the first days of the anticoagulant therapy.<sup>(<xref rid="B9" ref-type="bibr">9</xref>)</sup>
</p>
      <p>Once diagnosed, high doses of heparin should be administered, besides administration of vitamin K in order to restore proteins C and S levels.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B6" ref-type="bibr">6</xref>)</sup> The treatment includes the discontinuation of warfarin treatment, but this approach has not been shown to change the outcome. Success has been reported in careful recommencement of warfarin therapy, which in the beginning should be always associated to parenteral anticoagulation.<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup> Significant morbidity and several deaths have been also reported.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B10" ref-type="bibr">10</xref>)</sup> Despite that conservative treatment should be considered and half of cases requires surgical debridement,<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B7" ref-type="bibr">7</xref>)</sup> eventually mastectomy is needed.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B7" ref-type="bibr">7</xref>)</sup> No evidence was found regarding risk of skin necrosis by angiotensin-converting enzyme inhibitors as well as by phenobarbital. Moreover, antiepileptic drugs tend to reduce anticoagulants action.<sup>(<xref rid="B8" ref-type="bibr">8</xref>)</sup>
</p>
      <p>The usual characteristics founded in this case report corroborate with literature. In spite of complications presented: woman, 62-years-old, obese, necrosis occurrence on 6th day after introduction of oral anticoagulants for venous thrombosis. Despite the reduced dose and suspension of drug after the diagnosis, a simple mastectomy was necessary, because of the rapid evolution to the skin necrosis.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>DeFranzo</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Marasco</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Argenta</surname>
              <given-names>LC</given-names>
            </name>
          </person-group>
          <article-title>Warfarin-induced necrosis of the skin</article-title>
          <source>Ann Plast Surg</source>
          <year>1995</year>
          <volume>34</volume>
          <issue>2</issue>
          <fpage>203</fpage>
          <lpage>208</lpage>
          <comment>Review</comment>
          <pub-id pub-id-type="pmid">7741443</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flood</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Redish</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Bociek</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Piletromboflebites migrans disseminate: report of a case in which gangrene of the breast occurred. Observations on the therapeutic use of dicumarol (3,3&#x2019;methylenebis(4-hydroxycoumarin)</article-title>
          <source>N Y State J Med</source>
          <year>1943</year>
          <volume>43</volume>
          <fpage>1121</fpage>
          <lpage>1124</lpage>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Au</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Fosnot</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>LC</given-names>
            </name>
          </person-group>
          <article-title>Coumadin-induced skin necrosis of the breasts: case report</article-title>
          <source>Ann Plast Surg</source>
          <year>2012</year>
          <volume>69</volume>
          <issue>1</issue>
          <fpage>109</fpage>
          <lpage>110</lpage>
          <comment>Review</comment>
          <pub-id pub-id-type="pmid">21629052</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kagan</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Glassford</surname>
              <given-names>GH</given-names>
            </name>
          </person-group>
          <article-title>Coumadin-induced breast necrosis</article-title>
          <source>Am Surg</source>
          <year>1981</year>
          <volume>47</volume>
          <issue>11</issue>
          <fpage>509</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="pmid">7305140</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khalid</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Warfarin-induced necrosis of the breast: case report</article-title>
          <source>J Postgrad Med</source>
          <year>2004</year>
          <volume>50</volume>
          <issue>4</issue>
          <fpage>268</fpage>
          <lpage>269</lpage>
          <pub-id pub-id-type="pmid">15623967</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Valenti</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mansfield</surname>
              <given-names>AO</given-names>
            </name>
            <name>
              <surname>Stansby</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Warfarin induced skin necrosis</article-title>
          <source>Br J Surg</source>
          <year>2000</year>
          <volume>87</volume>
          <issue>3</issue>
          <fpage>266</fpage>
          <lpage>272</lpage>
          <comment>Review</comment>
          <pub-id pub-id-type="pmid">10718793</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>L&#xF3;pez Valle</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>H&#xE9;bert</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Warfarin-induced complete bilateral breast necrosis</article-title>
          <source>Br J Plast Surg</source>
          <year>1992</year>
          <volume>45</volume>
          <issue>8</issue>
          <fpage>606</fpage>
          <lpage>609</lpage>
          <comment>Review</comment>
          <pub-id pub-id-type="pmid">1493535</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bucciarelli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rosendaal</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Tripodi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mannucci</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>De Stefano</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Palareti</surname>
              <given-names>G</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <year>1999</year>
          <volume>19</volume>
          <issue>4</issue>
          <fpage>1026</fpage>
          <lpage>1033</lpage>
          <pub-id pub-id-type="pmid">10195932</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dahlb&#xE4;ck</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Villoutreix</surname>
              <given-names>BO</given-names>
            </name>
          </person-group>
          <article-title>The anticoagulant protein C pathway</article-title>
          <source>FEBS Lett</source>
          <year>2005</year>
          <volume>579</volume>
          <issue>15</issue>
          <fpage>3310</fpage>
          <lpage>3316</lpage>
          <comment>Review</comment>
          <pub-id pub-id-type="pmid">15943976</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ad-El</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Meirovitz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Weinberg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kogan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Arieli</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Neuman</surname>
              <given-names>A</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Warfarin skin necrosis: local and systemic factors</article-title>
          <source>Br J Plast Surg</source>
          <year>2000</year>
          <volume>53</volume>
          <issue>7</issue>
          <fpage>624</fpage>
          <lpage>626</lpage>
          <pub-id pub-id-type="pmid">11000083</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="TRpt" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato De Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Necrose mam&#xE1;ria induzida pelo uso de cumar&#xED;nico: relato de caso e revis&#xE3;o da literatura</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ejzenberg</surname>
            <given-names>Dani</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Neusquen</surname>
            <given-names>Lucienne Pereira Del Grossi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rolnik</surname>
            <given-names>Daniel Lorber</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lozinsky</surname>
            <given-names>Adriana Chebar</given-names>
          </name>
          <xref ref-type="aff" rid="aff2002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Piato</surname>
            <given-names>Jos&#xE9; Roberto Morales</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1002"><label>1</label>Hospital das Cl&#xED;nicas, Faculdade de Medicina, Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brasil.</aff>
      <aff id="aff2002"><label>2</label>Faculdade de Medicina do ABC, Santo Andr&#xE9;, SP, Brasil.</aff>
      <author-notes>
        <corresp>Autor correspondente: Dani Ejzenberg &#x2013; Avenida Rep&#xFA;blica do L&#xED;bano, 1.843 &#x2013; Ibirapuera &#x2013; CEP: 04501-002 &#x2013; S&#xE3;o Paulo, SP, Brasil &#x2013; Tel.: (11) 5055-1010 &#x2013; E-mail: <email>daejz@hotmail.com</email></corresp>
      </author-notes>
      <abstract>
        <p>A necrose cut&#xE2;nea induzida por cumar&#xED;nicos &#xE9; um evento raro e ocorre com maior frequ&#xEA;ncia nas mamas, coxas e n&#xE1;degas. Descrevemos o primeiro caso de necrose cumar&#xED;nica das mamas no Brasil em paciente de 62 anos.</p>
      </abstract>
      <kwd-group>
        <kwd>Necrose/quimicamente induzido</kwd>
        <kwd>Varfarina/efeitos adversos</kwd>
        <kwd>Mama/patologia</kwd>
        <kwd>Relatos de casos</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec>
        <title>INTRODU&#xC7;&#xC3;O</title>
        <p>A terapia anticoagulante &#xE9; frequentemente prescrita na pr&#xE1;tica m&#xE9;dica, sendo que uma das mais utilizadas &#xE9; a varfarina s&#xF3;dica.</p>
        <p>Uma complica&#xE7;&#xE3;o extremamente rara &#xE9; a necrose de pele e subcut&#xE2;nea, com incid&#xEA;ncia variando de 0,01% a 0,1%. As &#xE1;reas mais afetas s&#xE3;o as mamas, n&#xE1;degas e coxas.<sup>(<xref rid="B1" ref-type="bibr">1</xref>) </sup>O primeiro caso de necrose de pele afetando a mama foi relatado por Flood et al. em 1943.<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup> Desde ent&#xE3;o, quase 200 casos de necrose de pele foram relatados, por&#xE9;m menos de 40 envolveram o tecido mam&#xE1;rio.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup>
</p>
        <p>Tal ocorr&#xEA;ncia tem curso de a&#xE7;&#xE3;o irrevers&#xED;vel, e o diagn&#xF3;stico precoce e desbridamento cir&#xFA;rgico s&#xE3;o recomendados para prevenir morbidade significativa e mortalidade.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p>
      </sec>
      <sec>
        <title>RELATO DE CASO</title>
        <p>Paciente de 62 anos internada no Hospital das Cl&#xED;nicas, em S&#xE3;o Paulo (SP), devido &#xE0; dor na mama direita, incha&#xE7;o e escurecimento iniciados 3 dias antes da interna&#xE7;&#xE3;o. Os sintomas iniciaram no mamilo e se espalharam ao longo da mama direita. Seis dias antes das queixas, a paciente iniciou tratamento com varfarina s&#xF3;dica 2,5mg/dia para trombose venosa profunda da perna esquerda, por&#xE9;m sem uso simult&#xE2;neo de heparina. A trombose ocorreu em raz&#xE3;o de complica&#xE7;&#xE3;o na primeira sess&#xE3;o de braquiterapia para tratamento de c&#xE2;ncer cervical avan&#xE7;ado. A paciente tamb&#xE9;m recebia inibidores da enzima de convers&#xE3;o de angiotensina (captopril 150mg/dia) para hipertens&#xE3;o arterial e fenobarbital 50mg/dia para epilepsia. Ela negou consumo regular de &#xE1;lcool ou tabagismo.</p>
        <p>Na interna&#xE7;&#xE3;o, o estado geral da paciente era regular, com aus&#xEA;ncia de febre, press&#xE3;o sangu&#xED;nea de 130x90mmHg e &#xED;ndice de massa corporal de 32. Os exames abdominais, pulmonares e cardiol&#xF3;gicos estavam normais. A mama esquerda estava normal, por&#xE9;m a direita apresentava incha&#xE7;o e ulcera&#xE7;&#xE3;o extensa com base necr&#xF3;tica envolvendo a &#xE1;rea do mamilo e central (<xref rid="f01002" ref-type="fig">Figura 1</xref>).</p>
        <p>
<fig id="f01002" orientation="portrait" position="float"><label>Figura 1</label><caption><title>Necrose da mama direita induzida por cumar&#xED;nicos</title></caption><graphic xlink:href="1679-4508-eins-13-3-0417-gf01-pt"/></fig>
</p>
        <p>Os testes laboratoriais revelaram hemat&#xF3;crito de 29%, hemoglobina de 9,8mg/dL, contagem de gl&#xF3;bulos brancos de 6.450 e contagem de plaquetas de 142.000/mL. O tempo de protrombina foi de 14,7 segundos (normal: 11 segundos) com taxa internacional normalizada (INR) de 1,3 e tempo trombopl&#xE1;stico parcial normal. A fibrinogenemia tamb&#xE9;m foi normal, e os produtos de desintegra&#xE7;&#xE3;o de fibrina estavam altos (578&#x3BC;g/mL). A hip&#xF3;tese do diagn&#xF3;stico foi necrose da mama direita induzida pelo uso da varfarina. Administraram-se altas doses de heparina e vitamina K. Ap&#xF3;s 4 dias, como n&#xE3;o houve curso favor&#xE1;vel, a paciente foi submetida a mastectomia simples. N&#xE3;o foi observada intercorr&#xEA;ncia, e a administra&#xE7;&#xE3;o de heparina foi reiniciada 12 horas ap&#xF3;s a cirurgia. A paciente teve boa evolu&#xE7;&#xE3;o p&#xF3;s-operat&#xF3;ria e recebeu alta. A dose de terapia anticoagulante de 2,5mg/dia de varfarina foi readequada, sem o aparecimento de outras complica&#xE7;&#xF5;es.</p>
      </sec>
      <sec>
        <title>DISCUSS&#xC3;O</title>
        <p>A necrose de pele &#xE9; uma complica&#xE7;&#xE3;o incomum da terapia anticoagulante, e o envolvimento da mama ocorre em apenas 10 a 15% de casos.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup> A maioria das les&#xF5;es necr&#xF3;ticas aparece em &#xE1;reas com excesso de tecido subcut&#xE2;neo. Essas les&#xF5;es geralmente afetam mamas, coxas, bra&#xE7;os, n&#xE1;degas, m&#xE3;os, pontas dos dedos, pernas, p&#xE9;s, nariz, face, abd&#xF4;men, costas e p&#xEA;nis.<sup>(<xref rid="B5" ref-type="bibr">5</xref>)</sup> As mulheres s&#xE3;o mais afetadas do que os homens. Les&#xF5;es m&#xFA;ltiplas t&#xEA;m sido relatadas em 35% dos casos, algumas vezes simetricamente.<sup>(<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B5" ref-type="bibr">5</xref>)</sup>
</p>
        <p>Uma revis&#xE3;o da literatura de artigos publicados em l&#xED;ngua inglesa incluindo 25 manuscritos localizou 38 relatos de necrose de mama ap&#xF3;s uso de varfarina. A m&#xE9;dia de idade relatada nesses estudos foi de 16 a 93 anos.<sup>(<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B5" ref-type="bibr">5</xref>)</sup> N&#xE3;o houve diferen&#xE7;a significativa entre o envolvimento da mama direita ou esquerda, sendo que necrose bilateral tamb&#xE9;m foi relatada.<sup>(<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>)</sup> Geralmente, essa condi&#xE7;&#xE3;o &#xE9; observada em mulheres obesas de meia idade e que recebem terapia com varfarina para trombose venosa profunda ou outras doen&#xE7;as tromboemb&#xF3;licas, tal como ocorreu com a paciente deste relato de caso.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>)</sup>
</p>
        <p>A les&#xE3;o inicial consiste em eritematosa bem demarcada e &#xE1;rea dolorosa, que aparece entre 3 e 6 dias ap&#xF3;s o in&#xED;cio da anticoagula&#xE7;&#xE3;o.<sup>(<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>)</sup> Essa &#xE1;rea pode desenvolver aspecto em <italic>peau d&#x2019;orange </italic>(&#x201C;casca de laranja&#x201D;).<sup>(<xref rid="B5" ref-type="bibr">5</xref>)</sup> A &#xE1;rea afetada evolui para equimose escura, progredindo para tecido necr&#xF3;tico.<sup>(<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>) </sup>A histologia mostra infartos cut&#xE2;neos, hemorragias, obstru&#xE7;&#xE3;o das arter&#xED;olas pr&#xE9;-capilares e dep&#xF3;sitos fibrinosos, e n&#xE3;o evidencia inflama&#xE7;&#xE3;o vascular ou perivascular.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>) </sup>Alguns casos avan&#xE7;ados podem imitar carcinoma inflamat&#xF3;rio e, portanto, a realiza&#xE7;&#xE3;o de bi&#xF3;psia precocemente ajuda no diagn&#xF3;stico diferencial.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
</p>
        <p>A etiologia exata e o motivo para sua predile&#xE7;&#xE3;o para tecido adiposo permanecem incertos, mas muitos autores acreditam que &#xE9; uma condi&#xE7;&#xE3;o multifatorial, que pode incluir trauma, perfus&#xE3;o sangu&#xED;nea inadequada e varia&#xE7;&#xE3;o de temperatura.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B7" ref-type="bibr">7</xref>)</sup> O prov&#xE1;vel mecanismo que desencadeia tal complica&#xE7;&#xE3;o &#xE9; a pequena trombose das veias cut&#xE2;neas, devido &#xE0; inibi&#xE7;&#xE3;o da prote&#xED;na C e S, e da vitamina K-dependente de anticoagulante endovenosos. Tal situa&#xE7;&#xE3;o ocorre antes da inibi&#xE7;&#xE3;o de outros fatores e leva &#xE0; tend&#xEA;ncia trombol&#xED;tica entre indiv&#xED;duos que apresentam defici&#xEA;ncias homozigota, heterozigota ou de absor&#xE7;&#xE3;o de prote&#xED;nas C e S.<sup>(<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>) </sup>Por esta raz&#xE3;o, muitos autores recomendam administra&#xE7;&#xE3;o concomitante de heparina nos primeiros dias de terapia anticoagulante.<sup>(<xref rid="B9" ref-type="bibr">9</xref>)</sup>
</p>
        <p>Uma vez diagnosticado, a administra&#xE7;&#xE3;o de alta dose de heparina deve ser iniciada, al&#xE9;m de vitamina K para restaura&#xE7;&#xE3;o dos n&#xED;veis de prote&#xED;nas C e S.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B6" ref-type="bibr">6</xref>)</sup> O tratamento inclui a suspens&#xE3;o da varfarina, por&#xE9;m tal quest&#xE3;o n&#xE3;o tem demonstrado altera&#xE7;&#xE3;o no resultado. Sucesso tem sido relatado no rein&#xED;cio cauteloso da terapia com varfarina, cujo in&#xED;cio deve ser sempre associado &#xE0; anticoagula&#xE7;&#xE3;o parenteral.<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup> Morbidade significativa e diversas mortes t&#xEA;m sido relatadas.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B10" ref-type="bibr">10</xref>)</sup> Todavia, o tratamento conservador deve ser considerado. Embora o tratamento conservador deva ser considerado e metade dos casos demande o desbridamento,<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B7" ref-type="bibr">7</xref>)</sup> a mastectomia eventualmente &#xE9; necess&#xE1;ria.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B7" ref-type="bibr">7</xref>)</sup> N&#xE3;o foi observado risco de necrose cut&#xE2;nea induzida por inibidores da enzima de convers&#xE3;o de angiotensina, assim como como por fenobarbital. Al&#xE9;m disso, os medicamentos antiepil&#xE9;pticos tendem a reduzir a a&#xE7;&#xE3;o anticoagulante.<sup>(<xref rid="B8" ref-type="bibr">8</xref>)</sup>
</p>
        <p>O caso descrito neste relato corrobora as caracter&#xED;sticas comuns descritas na literatura, apesar da complica&#xE7;&#xE3;o espec&#xED;fica deste caso: mulher, 62 anos, obesa, com ocorr&#xEA;ncia de necrose no 6 dia ap&#xF3;s introdu&#xE7;&#xE3;o de anticoagulante oral para trombose venosa. Apesar de a medica&#xE7;&#xE3;o ter sido reduzida e suspensa no diagn&#xF3;stico, foi necess&#xE1;rio realizar mastectomia simples, em raz&#xE3;o da r&#xE1;pida evolu&#xE7;&#xE3;o da necrose da pele.</p>
      </sec>
    </body>
  </sub-article>
</article>
</pmc-articleset>
